2. >>Products

NHS And Sandoz Look Into Natalizumab Switching Reports

Media Reports Indicate Adverse Reactions From Patients At A UK Hospital

 
• By Dave Wallace

The UK’s NHS and Sandoz have both told Generics Bulletin that they are looking into reports from a single UK hospital of adverse reactions linked to patients that have switched from Tysabri to Sandoz’s Tyruko biosimilar.

The reports came from Charing Cross hospital (Shutterstock)

The UK National Health Service and Sandoz have confirmed that they are investigating reports from a single UK hospital of adverse reactions from patients after switching between Biogen’s Tysabri (natalizumab) and Sandoz’s Tyruko biosimilar.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

Rage Against The Machine: Generics CEOs Slam Systemic Problems In The US

 
• By Dave Wallace

During the “CEOs Unplugged” panel at the AAM’s annual conference in February, leaders from Sandoz, Lupin and Amneal discussed the various ways in which the US framework is making life difficult for generics and biosimilars.

Samsung Bioepis Grows After US Launches

 
• By Dave Wallace

Samsung Bioepis has revealed first-quarter figures that reflect recent launches driving growth for the Korean biosimilars developer.

French Body Welcomes Call For Greater Uptake

 
• By Dave Wallace

French generics and biosimilar body Gemme has welcomed a call from the country’s audit court to improve uptake for off-patent medicines.

Celltrion Celebrates Interchangeability Designation For Humira Biosimilar In The US

 
• By Urtė Fultinavičiūtė

Celltrion’s adalimumab biosimilar was crowned as interchangeable by the FDA, at a time when the future of the designation is unknown.

More from Business